Skip to main content
Top
Published in: Clinical Drug Investigation 10/2006

01-10-2006 | Case Reports

Psychotic Disorder Induced by Oxybutynin

Presentation of Two Cases

Authors: Dr Murat Gulsun, Murat Pinar, Unal Sabanci

Published in: Clinical Drug Investigation | Issue 10/2006

Login to get access

Abstract

Anticholinergic agents are muscarinic receptor antagonists that suppress the activity of the acetylcholine system in the brain. Some of these agents also increase the concentration of dopamine in the synaptic cleft, which may result in psychotic symptoms. Oxybutynin is an antimuscarinic drug that may have adverse effects on the CNS, including memory impairment, confusion, delirium and hallucinations in elderly patients. To date, several case reports have been published about the association between oxybutynin and psychotic symptoms in elderly subjects, but we were unable to find any case reports describing oxybutynin-induced psychotic disorders in young people. Here we report on two patients, a 7-year-old boy and a 21-year-old man, who developed a brief psychotic disorder that may have been caused by oxybutynin.
The first patient was kept under observation with vital functions supported but no medication. All his psychotic symptoms regressed and his general condition improved. The second patient was treated with olanzapine 10 mg/ day. His psychotic symptoms resolved within 3 weeks. Our two case reports provide evidence that oxybutynin may induce psychotic disorders, and in younger patients.
Literature
1.
go back to reference Malkowicz SB, Wein AJ, Ruggieri MR, et al. Comparison of calcium antagonist properties of antispasmodic agents. J Urol 1987; 138(3): 667–70PubMed Malkowicz SB, Wein AJ, Ruggieri MR, et al. Comparison of calcium antagonist properties of antispasmodic agents. J Urol 1987; 138(3): 667–70PubMed
2.
go back to reference Int’Veld BA, Kwee-Zuiderwijk WJ, van Puijenbroek EP, et al. Neuropsychiatric adverse effects attributed to use of oxybutynin. Ned Tijdschr Geneeskd 1998; 142(11): 590–2 Int’Veld BA, Kwee-Zuiderwijk WJ, van Puijenbroek EP, et al. Neuropsychiatric adverse effects attributed to use of oxybutynin. Ned Tijdschr Geneeskd 1998; 142(11): 590–2
3.
go back to reference British Medical Association, Royal Pharmaceutical Society of Great Britain. British National Formulary. No 34. London: BMA,RPS, 1997 British Medical Association, Royal Pharmaceutical Society of Great Britain. British National Formulary. No 34. London: BMA,RPS, 1997
4.
go back to reference American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington,DC: American Psychiatric Association, 1994 American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington,DC: American Psychiatric Association, 1994
5.
go back to reference Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239–45PubMedCrossRef Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239–45PubMedCrossRef
6.
go back to reference Guy W. ECDEU assessment manual for psychopharmacology — revised (DHEW Publ. No. ADM 76-338). Rockville, MD: US Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs, 1976: 218-22 Guy W. ECDEU assessment manual for psychopharmacology — revised (DHEW Publ. No. ADM 76-338). Rockville, MD: US Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs, 1976: 218-22
8.
go back to reference Donnellan CA, Fook L, McDonald P, et al. Oxybutynin and cognitive dysfunction. BMJ 1997; 315: 1363–4PubMedCrossRef Donnellan CA, Fook L, McDonald P, et al. Oxybutynin and cognitive dysfunction. BMJ 1997; 315: 1363–4PubMedCrossRef
9.
go back to reference Adcock EW. Cyclopentolate (Cyclogyl) toxicity in pediatric patients. Pediatr Pharmacol Ther 1971; 79: 127–9 Adcock EW. Cyclopentolate (Cyclogyl) toxicity in pediatric patients. Pediatr Pharmacol Ther 1971; 79: 127–9
10.
go back to reference Ananth JV, Jain RC. Benztropine psychosis. Can Psychiatr Assoc J 1973; 18: 409–14PubMed Ananth JV, Jain RC. Benztropine psychosis. Can Psychiatr Assoc J 1973; 18: 409–14PubMed
11.
go back to reference Anath JV, Lehman HE, Ban TA. Toxic psychosis induced by benzhexol hydrochloride. CMAJ 1970; 103: 771 Anath JV, Lehman HE, Ban TA. Toxic psychosis induced by benzhexol hydrochloride. CMAJ 1970; 103: 771
12.
go back to reference Bernstein S, Leff R. Toxic psychosis from sleeping medicines containing scopolamine. N Engl J Med 1967; 277: 638–9PubMedCrossRef Bernstein S, Leff R. Toxic psychosis from sleeping medicines containing scopolamine. N Engl J Med 1967; 277: 638–9PubMedCrossRef
13.
go back to reference Duvoisin RC, Katz R. Reversal of central anticholinergic syndrome in man by physostigmine. JAMA 1968; 206: 1963–5PubMedCrossRef Duvoisin RC, Katz R. Reversal of central anticholinergic syndrome in man by physostigmine. JAMA 1968; 206: 1963–5PubMedCrossRef
14.
15.
go back to reference Granacher RP, Baldessarini RJ. Physostigmine treatment of delirium induced by anticholinergics. Am Fam Physician 1976; 13: 99–103PubMed Granacher RP, Baldessarini RJ. Physostigmine treatment of delirium induced by anticholinergics. Am Fam Physician 1976; 13: 99–103PubMed
16.
go back to reference Granacher RP, Baldessarini RJ. Physostigmine: its use in acute anticholinergic syndrome with antidepressant and antiparkinson drugs. Arch Gen Psychiatry 1975; 32: 375–82PubMedCrossRef Granacher RP, Baldessarini RJ. Physostigmine: its use in acute anticholinergic syndrome with antidepressant and antiparkinson drugs. Arch Gen Psychiatry 1975; 32: 375–82PubMedCrossRef
18.
go back to reference Heiser JF, Gillin JC. The reversal of anticholinergic druginduced delirium and coma with physostigmine. Am J Psychiatry 1971; 127: 1050–4PubMed Heiser JF, Gillin JC. The reversal of anticholinergic druginduced delirium and coma with physostigmine. Am J Psychiatry 1971; 127: 1050–4PubMed
19.
go back to reference Johnson CE. Mystical force of the nightshade. Int J Neuropsychiatry 1967; 3: 268–75PubMed Johnson CE. Mystical force of the nightshade. Int J Neuropsychiatry 1967; 3: 268–75PubMed
20.
go back to reference Mikolich JR, Paulson GW, Cross CJ. Acute anticholinergic syndrome due to jimson seed ingestion. Ann Intern Med 1975; 83: 321–5PubMed Mikolich JR, Paulson GW, Cross CJ. Acute anticholinergic syndrome due to jimson seed ingestion. Ann Intern Med 1975; 83: 321–5PubMed
21.
go back to reference Rumack BH. Anticholinergic poisoning: treatment with physostigmine. Pediatrics 1973; 52: 449–51PubMed Rumack BH. Anticholinergic poisoning: treatment with physostigmine. Pediatrics 1973; 52: 449–51PubMed
22.
go back to reference Shader RI, Greenblatt DJ. Belladonna alkaloids and synthetic anticholinergics: uses and toxicity. In: Shader RI, editor. Psychiatric complications of medical drugs. New York: Raven Press, 1972: 102–47 Shader RI, Greenblatt DJ. Belladonna alkaloids and synthetic anticholinergics: uses and toxicity. In: Shader RI, editor. Psychiatric complications of medical drugs. New York: Raven Press, 1972: 102–47
23.
go back to reference Shafer DJ, Allen RP. The central effects of scopolamine in man. Biol Psychiatry 1971; 3: 347–55 Shafer DJ, Allen RP. The central effects of scopolamine in man. Biol Psychiatry 1971; 3: 347–55
24.
go back to reference Ullman KC, Groh RH, Wolff FW. Treatment of scopolamineinduced delirium. Lancet 1970; I: 252CrossRef Ullman KC, Groh RH, Wolff FW. Treatment of scopolamineinduced delirium. Lancet 1970; I: 252CrossRef
25.
go back to reference Pietzko A, Dimpfel W, Schwantes U, et al. Influences of trospium chloride and oxybutynin on quantitative EEG in healthy volunteers. Eur J Clin Pharmacol 1994; 47(4): 337–43PubMedCrossRef Pietzko A, Dimpfel W, Schwantes U, et al. Influences of trospium chloride and oxybutynin on quantitative EEG in healthy volunteers. Eur J Clin Pharmacol 1994; 47(4): 337–43PubMedCrossRef
26.
go back to reference Jonville AP, Dutertre JP, Autret E, et al. Effets indésirables du chlorure d’oxybutynine (Ditropan). Bilan de l’enquete officielle des Centres Régionaux de Pharmacovigilance. Therapie 1992; 47: 389–92PubMed Jonville AP, Dutertre JP, Autret E, et al. Effets indésirables du chlorure d’oxybutynine (Ditropan). Bilan de l’enquete officielle des Centres Régionaux de Pharmacovigilance. Therapie 1992; 47: 389–92PubMed
27.
go back to reference Valsecia ME, Malgor LA, Espíndola JH, et al. New adverse effect of oxybutynin: ‘night terror’ [letter]. Ann Pharmacother 1998; 32: 506PubMedCrossRef Valsecia ME, Malgor LA, Espíndola JH, et al. New adverse effect of oxybutynin: ‘night terror’ [letter]. Ann Pharmacother 1998; 32: 506PubMedCrossRef
Metadata
Title
Psychotic Disorder Induced by Oxybutynin
Presentation of Two Cases
Authors
Dr Murat Gulsun
Murat Pinar
Unal Sabanci
Publication date
01-10-2006
Publisher
Springer International Publishing
Published in
Clinical Drug Investigation / Issue 10/2006
Print ISSN: 1173-2563
Electronic ISSN: 1179-1918
DOI
https://doi.org/10.2165/00044011-200626100-00007

Other articles of this Issue 10/2006

Clinical Drug Investigation 10/2006 Go to the issue